Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation (BOREALIS-AF)

This study has been terminated.
(early discontinuation based on strategic sponsor decision not driven by any safety concern)
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT00580216
First received: December 21, 2007
Last updated: February 26, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2010
  Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)